News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
742,107 Results
Type
Article (45190)
Company Profile (340)
Press Release (696566)
Multimedia
Podcasts (127)
Webinars (21)
Section
Business (212766)
Career Advice (2194)
Deals (37185)
Drug Delivery (122)
Drug Development (84485)
Employer Resources (178)
FDA (16892)
Job Trends (15657)
News (360923)
Policy (34614)
Tag
Academia (2636)
Accelerated approval (16)
Adcomms (32)
Allergies (126)
Alliances (52223)
ALS (141)
Alzheimer's disease (1600)
Antibody-drug conjugate (ADC) (254)
Approvals (16979)
Artificial intelligence (438)
Autoimmune disease (97)
Automation (30)
Bankruptcy (378)
Best Places to Work (11843)
BIOSECURE Act (22)
Biosimilars (164)
Biotechnology (194)
Bladder cancer (133)
Brain cancer (49)
Breast cancer (510)
Cancer (4026)
Cardiovascular disease (347)
Career advice (1845)
Career pathing (36)
CAR-T (240)
CDC (48)
Cell therapy (645)
Cervical cancer (31)
Clinical research (70848)
Collaboration (1400)
Company closure (4)
Compensation (959)
Complete response letters (57)
COVID-19 (2782)
CRISPR (82)
C-suite (605)
Cystic fibrosis (136)
Data (4877)
Decentralized trials (2)
Denatured (37)
Depression (103)
Diabetes (447)
Diagnostics (6668)
Digital health (34)
Diversity (12)
Diversity, equity & inclusion (46)
Drug discovery (203)
Drug pricing (188)
Drug shortages (34)
Duchenne muscular dystrophy (201)
Earnings (91350)
Editorial (50)
Employer branding (21)
Employer resources (157)
Events (119859)
Executive appointments (960)
FDA (19422)
Fibrodysplasia Ossificans Progressiva (4)
Friedreich's ataxia (6)
Frontotemporal dementia (15)
Funding (1236)
Gene editing (174)
Generative AI (37)
Gene therapy (520)
GLP-1 (983)
Government (4826)
Grass and pollen (7)
Guidances (372)
Healthcare (19191)
HIV (44)
Huntington's disease (37)
IgA nephropathy (67)
Immunology and inflammation (237)
Immuno-oncology (19)
Indications (60)
Infectious disease (3019)
Inflammatory bowel disease (180)
Inflation Reduction Act (13)
Influenza (93)
Intellectual property (197)
Interviews (344)
IPO (17057)
IRA (56)
Job creations (4173)
Job search strategy (1560)
Kidney cancer (16)
Labor market (75)
Layoffs (589)
Leadership (35)
Legal (8568)
Liver cancer (86)
Longevity (12)
Lung cancer (571)
Lymphoma (283)
Machine learning (31)
Management (62)
Manufacturing (638)
MASH (143)
Medical device (13773)
Medtech (13800)
Mergers & acquisitions (21031)
Metabolic disorders (1147)
Multiple sclerosis (139)
NASH (20)
Neurodegenerative disease (220)
Neuropsychiatric disorders (58)
Neuroscience (2623)
NextGen: Class of 2025 (6732)
Non-profit (4572)
Now hiring (59)
Obesity (556)
Opinion (287)
Ovarian cancer (141)
Pain (172)
Pancreatic cancer (172)
Parkinson's disease (237)
Partnered (29)
Patents (422)
Patient recruitment (332)
Peanut (56)
People (60841)
Pharmaceutical (100)
Pharmacy benefit managers (29)
Phase I (22063)
Phase II (31097)
Phase III (23320)
Pipeline (2896)
Policy (279)
Postmarket research (2687)
Preclinical (9361)
Press Release (68)
Prostate cancer (198)
Psychedelics (44)
Radiopharmaceuticals (267)
Rare diseases (670)
Real estate (6397)
Recruiting (71)
Regulatory (24802)
Reports (51)
Research institute (2429)
Resumes & cover letters (372)
Rett syndrome (16)
RNA editing (13)
RSV (75)
Schizophrenia (135)
Series A (202)
Series B (153)
Service/supplier (14)
Sickle cell disease (80)
Special edition (25)
Spinal muscular atrophy (155)
Sponsored (37)
Startups (3820)
State (2)
Stomach cancer (16)
Supply chain (100)
Tariffs (95)
The Weekly (88)
Vaccines (959)
Venture capital (66)
Weight loss (388)
Women's health (58)
Worklife (18)
Date
Today (210)
Last 7 days (999)
Last 30 days (3149)
Last 365 days (31550)
2025 (26799)
2024 (36149)
2023 (40930)
2022 (52114)
2021 (56674)
2020 (55108)
2019 (47821)
2018 (36139)
2017 (33569)
2016 (33169)
2015 (39008)
2014 (32960)
2013 (28077)
2012 (30165)
2011 (30871)
2010 (28889)
Location
Africa (822)
Alabama (73)
Alaska (7)
Arizona (283)
Arkansas (14)
Asia (42636)
Australia (6771)
California (9626)
Canada (2904)
China (921)
Colorado (400)
Connecticut (410)
Delaware (273)
Europe (91775)
Florida (1448)
Georgia (307)
Hawaii (2)
Idaho (60)
Illinois (742)
India (51)
Indiana (473)
Iowa (18)
Japan (337)
Kansas (120)
Kentucky (34)
Louisiana (19)
Maine (69)
Maryland (1261)
Massachusetts (7047)
Michigan (288)
Minnesota (555)
Mississippi (4)
Missouri (111)
Montana (29)
Nebraska (25)
Nevada (108)
New Hampshire (72)
New Jersey (2649)
New Mexico (31)
New York (2584)
North Carolina (1333)
North Dakota (8)
Northern California (4513)
Ohio (291)
Oklahoma (21)
Oregon (43)
Pennsylvania (2011)
Puerto Rico (20)
Rhode Island (43)
South America (1187)
South Carolina (51)
South Dakota (1)
Southern California (3692)
Tennessee (150)
Texas (1486)
United States (34895)
Utah (289)
Virginia (238)
Washington D.C. (78)
Washington State (796)
West Virginia (4)
Wisconsin (86)
Wyoming (2)
742,107 Results for "atyr pharma inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Foundation for Sarcoidosis Research Reacts to the Announcement of aTyr Pharma’s Phase 3 Clinical Trial Results
September 18, 2025
·
3 min read
Press Releases
aTyr Pharma Announces Topline Results from Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis
September 15, 2025
·
10 min read
Press Releases
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - September 5, 2025
September 8, 2025
·
1 min read
Press Releases
aTyr Pharma Announces Second Quarter 2025 Results and Provides Corporate Update
August 8, 2025
·
10 min read
Press Releases
aTyr Pharma Presents Additional Findings from Phase 3 EFZO-FIT™ Study in Late-Breaking Oral Abstract at the European Respiratory Society (ERS) Congress 2025
September 30, 2025
·
7 min read
Press Releases
aTyr Pharma Advances ATYR0101 to IND Candidate Stage for Pulmonary Fibrosis
May 15, 2025
·
5 min read
Press Releases
aTyr Pharma Announces Last Patient Visit in Phase 3 EFZO-FIT™ Study of Efzofitimod in Patients with Pulmonary Sarcoidosis
July 23, 2025
·
5 min read
Biotech Beach
aTyr Pharma Announces Nasdaq Stock Ticker Symbol Change from “LIFE” to “ATYR”
aTyr Pharma, Inc. announced that the Company will be changing its ticker symbol from “LIFE” to “ATYR.” Effective at the market open on June 5, 2024, the Company’s common stock will trade on the Nasdaq Capital Market under the new symbol “ATYR.”
June 3, 2024
·
4 min read
Press Releases
aTyr Pharma to Participate in April Investor Conferences
April 3, 2025
·
1 min read
Press Releases
aTyr Pharma to Present at Upcoming Investor Conferences scheduled to take place in May and June 2025
May 20, 2025
·
2 min read
1 of 74,211
Next
